{
    "nctId": "NCT00319254",
    "briefTitle": "Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer",
    "officialTitle": "Phase II Study Of SKI-606 In Subjects With Advanced Or Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms, Neoplasm Metastasis",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 75,
    "primaryOutcomeMeasure": "Progression-Free Survival (PFS) Rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Stage IIIB, IIIC or IV breast cancer not curable with available therapy.\n* Patients must have progressed after 1 but not more than 3 prior chemotherapy regimens.\n* Life expectancy of at least 16 weeks.\n* Ability to swallow whole capsules.\n\nExclusion Criteria:\n\n* Use of or requirement for bisphosphonates within 8 weeks prior to screening.\n* Any other cancer within 5 years of screening, except for basal cell carcinoma or cervical carcinoma in situ\n* Uncontrolled cardiac disease including congestive heart failure, angina, heart attack, etc.\n* Recent or ongoing significant gastrointestinal disorder",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}